Clarus Securities

Concussion-focused Scythian sets market debut

By GREGORY ZELLER // Scythian Biosciences Corp. is going public. The New York City/Toronto-based biotech, led by Great Neck investment banker Jonathan Gilbert on its quest to develop the world’s first pharmaceutical treatment for concussions, will begin trading Aug. 8 on the TSX Venture Exchange, one of Canada’s major stock markets. Projected to open at $8 (Canadian) per share, Scythian Biosciences (ticker symbol “SCYB”) will float upwards of 2.5 million shares – about half of…


Stock deal locks funds for Scythian marijuana study

By GREGORY ZELLER // A Canadian R&D firm with Long Island roots has locked up the first tranche of a strategic investment that will fund a major study involving concussions and medical marijuana. Scythian Biosciences Inc. and Canadian mining exploration company Kitrinor Metals Inc. on Tuesday announced a “brokered private placement” that gives 32.7 million common shares of Calgary-based Scythian, owned by Great Neck investment banker Jonathan Gilbert, to an investment team including lead agent…